DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1947)

Heart Failure | Landscape & Forecast | Disease Landscape & Forecast

Heart Failure | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress has been made in the pharmacological management of HF, it is mainly in chronic HF (CHF) with reduced ejection fraction (HFrEF); a significant unmet need remains for CHF with preserved ejection fraction (HFpEF). In addition, the treatment of acute HF (AHF) is dominated by older, generic products. We provide insights into the continued uptake of Entresto over the 2017-2027 forecast period, and its expected launch for HFpEF in 2020. We also examine the potential of several new therapies for CHF (Boehringer Ingelheim/Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Lexicon Pharmaceuticals/Sanofi’s sotagliflozin, Bayer/MSD’s vericiguat, and Amgen/Cytokinetics’s omecamtiv mecarbil), and assess how the AHF market will evolve given the lack of new drug launches.

Questions Answered

  • How large is the treatable HF population and how will diagnosis rates change over time?
  • What is the current state of treatment in HF? Which drugs are the most important and why? What clinical needs remain unfulfilled?
  • How is the use of Entresto going to evolve over the forecast period and will it reach blockbuster status?
  • How is the treatment of HFpEF going to evolve following the launches of the first evidence-based drugs for this population?
  • For which emerging therapies do thought leaders express the most enthusiasm? What level of market penetration can we expect of new therapies given the increasingly crowded and competitive landscape?

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • February 2019
      • December 2018
      • September 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Heart Failure?
        • What Factors Are Constraining the Market for Heart Failure?
      • Drug-Class-Specific Trends
        • Loop Diuretics
        • Inotropic Sympathomimetics, Phosphodiesterase 3 Inhibitors, and Calcium Sensitizers
        • Natriuretic Peptide Receptor Agonists
        • ACE Inhibitors
        • AIIRA/ARBs
        • Angiotensin Receptor-Neprilysin Inhibitors
        • HCN Channel Blockers
        • Mineralocorticoid Receptor Antagonists
        • Soluble Guanylate Cyclase Stimulators
        • Sodium-Glucose Cotransporter 2 Inhibitors
        • Cardiac Myosin Activators
    • Forecast
      • Market Forecast Assumptions - AHF
      • Market Forecast Assumptions - CHF
      • Market Forecast Dashboard - AHF
      • Market Forecast Dashboard - CHF
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Heart Failure Development
      • Heart Failure Stages
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Events of Acute Heart Failure
        • Diagnosed Prevalent Cases of Chronic Heart Failure
        • Diagnosed Prevalent Cases of Chronic Heart Failure by NYHA-Functional Classification Scheme
        • Diagnosed Prevalent Cases of Chronic Heart Failure by Ejection Fraction
        • Drug-Treated Prevalent Cases of CHF and Events of AHF
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Loop Diuretics IV
        • Loop Diuretics Oral
        • Nitrate Vasodilators
        • Inotropic Sympathomimetics
        • Phosphodiesterase 3 Inhibitors
        • Natriuretic Peptide Receptor Agonists
        • Calcium Sensitizers
        • ACE Inhibitors
        • AIIRA/ARBs
        • ARNI
        • Beta Blockers
        • Mineralocorticoid Receptor Antagonists
        • Digitalis Glycosides
        • HCN Channel Blockers
        • Vasodilator Combination Therapies
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Heart Failure
    • Emerging Therapies
      • Key Findings
        • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Heart Failure
        • Nitroxyl Donors
        • Soluble Guanylate Cyclase Stimulators
        • Sodium-Glucose Cotransporter-2 Inhibitors
        • Cardiac Myosin Activators
        • Stem Cell Therapies
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Heart Failure
      • Key Discontinuations and Failures in Heart Failure
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Heart Failure Bibliography

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Dominika Rudnicka-Noulin, PhD, MSc; Sunali D. Goonesekera, SM
  • Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome. Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions

  • Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Purchase Report

Recent reports:
You may also be interested in: